From 6 months to 35 months

For the 2017 influenza season, the following quadrivalent influenza vaccine will be registered and available for use in children from 6 months to 35 months (less than 3 years):

Sanofi-Aventis – FluQuadri Junior

From the age of 3 years

For the 2017 influenza season, in addition to the quadrivalent vaccines mentioned above, the following quadrivalent influenza vaccines will be registered and available for use in children from the age of 3 years:

GlaxoSmithKline – Fluarix Tetra

Sanofi-Aventis – FluQuadri

Vaccine strains for 2017

Following a review of the strains of influenza that were circulating in Australia and the Southern Hemisphere in the winter of 2016, the Australian Influenza Vaccine Committee (AIVC) recommended that the TGA should adopt the September 2016 World Health Organization (WHO) recommendations for the strains to be covered by the 2017 seasonal influenza vaccines. Details of the strains were announced on the TGA website on 25 October 2016.

This year, only quadrivalent vaccines will be available. Quadrivalent vaccines include two influenza A strains and two B strains.

Reporting of adverse events following influenza vaccine

Health professionals and consumers are encouraged to report all adverse events associated with influenza vaccination in patients of any age to the TGA or through the current arrangements in their State or Territory.

All reports contribute to the TGA's ongoing monitoring of the safety of influenza vaccines.

The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a vaccine or medicine.